Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Verrica Pharmaceuticals Inc.

< Previous 1 2 3 Next >
News headline image
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
News headline image
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.